Mary Teeling, MD Pharm
Mary Teeling is a specialist pharmaceutical physician with over 30 years’ experience in the areas of pharmacology and pharmaceutical medicine. She developed the Master of Science (MSc) in Pharmaceutical Medicine in 2004, while working in Trinity College Dublin, and was course director up until 2018. As assistant professor in the School of Medicine in Trinity College Dublin, her main research interest was in the area of pharmacoepidemiology, including prescribing patterns, influences on prescribing, quality indicators, rational prescribing, and pharmacovigilance. Currently, she is adjunct professor of pharmaceutical medicine within the department of Pharmacology and Therapeutics.
She also worked as a part-time medical advisor to the National Medicines Information Centre (NMIC) for 17 years up until 2018, where her role involved writing therapeutics bulletins and newsletters for healthcare professionals and providing education on safe prescribing for doctors in training. Prior to working in Trinity College Dublin and NMIC, she worked in the Irish Medicines Board (now Health Products Regulatory Authority) for 12 years and was its medical director for six years. She was the Irish member of the EU Committee for Human Medicinal Products (CHMP) and served as its vice-chair for three years.
Teeling was part of the educational team that developed the higher speciality training (HST) programme in pharmaceutical medicine with the Royal College of Physicians in Ireland, which achieved approval from the Medical Council of Ireland in 2016. She is the current national specialty director (NSD) for the programme. She is a member of the NDA Regulatory Advisory Board, which is composed of other former EU regulatory and industry experts (www.ndareg.com). She is an honorary consultant for the review panel of the WHO Uppsala Monitoring Centre (UMC) involved in safety signal identification.